OR WAIT 15 SECS
STA Pharmaceuticals and BioLingus have announced the formation of an exclusive technology and marketing collaboration for sublingual delivery.
STA Pharmaceuticals (WuXi STA) and Swiss biotech company, BioLingus, have announced in a Feb. 18, 2019 press release, the formation of an exclusive technology and marketing collaboration for sublingual delivery.
Under the terms of the agreement, BioLingus will grant WuXi STA exclusive access to its technology for sublingual and buccal delivery within the contract development and manufacturing organization (CDMO) sector. The novel platform from BioLingus enables the stabilization and sublingual delivery of drug targets, including small molecules, peptides, and proteins that are currently administered to patients via injection.
“We entered into this exclusive collaboration with WuXi STA for this technology in the CDMO sector for a number of reasons. Principally, WuXi STA is one of the world leaders in this field, with an integrated CMC platform from pre-clinical development to commercialization,” said Yves Decadt, CEO of BioLingus. “Furthermore,this partnership will help us develop our own client base on a global scale faster and more broadly than we could do on our own.”
“We are very pleased to partner with BioLingus and to offer their award-winning sublingual delivery technology to global new drug developers via WuXi STA’s integrated CMC platform,” added Minzhang Chen, CEO of WuXi STA. “This collaboration will therefore offer more economical, convenient, and effective delivery solutions for patients globally.”
Source: WuXi STA